Liraglutide Injection 18?mg/3?ml Prefilled Pen | Tonboli by Tonghua Dongbao |

Liraglutide Injection 18?mg/3?ml Prefilled Pen | Tonboli by Tonghua Dongbao |

(1 条用户评价)

$2.00

Liraglutide 18?mg in a 3?ml prefilled pen, branded Tonboli, produced by Tonghua Dongbao Pharmaceutical Co., Ltd. Approved under NMPA S20230066, ideal for GLP?1 receptor agonist research, metabolic studies, and diabetes modelling.
?? For laboratory research use only – Not for human consumption or therapeutic use.

EMI starting from $0.00/month - View Plans
Compare
分类:

描述

 Description

Product name: Liraglutide injection (Tongboli/Dongbao)
Packaging specifications: Pre-filled 3ml:18mg ? Product dosage form: injection ? Packaging unit: stick/box
Approval number: National Medicine Standard S20230066 ? Drug code: 86903546001121
Manufacturer: Tonghua Dongbao Pharmaceutical Co., Ltd.

Liraglutide Injection (Tonboli) is a domestically manufactured GLP?1 receptor agonist and the second Chinese-made solution approved for type 2 diabetes treatment. Developed as a biosimilar to Novo Nordisk’s Victoza®, it received regulatory approval under NMPA S20230066 in December 2023?.

  • Active Ingredient: Liraglutide, a 97% human GLP?1 analog peptide

  • Formulation: 18?mg of liraglutide in 3?ml of isotonic, clear solution with stabilizers and phenol?

  • Delivery: Single-dose, prefilled auto-injector pen

  • Source: Approved by NMPA, produced by Tonghua Dongbao?

This innovative biodrug is a key addition to China’s growing family of GLP?1RAs, enabling research into glucose regulation, weight control, cardiovascular effects, and peptide-based therapy mechanisms?.


 Product Specifications

Feature Details
Product Name Liraglutide Prefilled Injection Pen (Tonboli)
Strength 18?mg in 3?ml (6?mg/ml)
Form Prefilled pen injection
Manufacturer Tonghua Dongbao Pharmaceutical Co., Ltd.
Approval Number (NMPA) S20230066
Product Code 86903546001121
Area of Registration Class 3.3 therapeutic biologic
Storage Conditions Refrigerate at 2–8?°C; protect from light; do not freeze
Shelf Life 30 months (first-use pen: 30 days at ?30?°C)
Appearance Clear, colorless, isotonic solution?
Barcode (Insert if available)
Intended Use For laboratory research / analytical study only

 Mechanism & Clinical Data

  • GLP?1 receptor activation promotes insulin secretion, suppresses glucagon, and slows gastric emptying?.

  • Approved for glycaemic control in adults with T2DM; Tonboli represents China’s second domestic GLP?1RA?.

  • Tonghua Dongbao continues advancing its GLP?1 pipeline, including semaglutide and GLP?1/GIP dual agonists?.

  • International rollout is supported through cooperation with Sinovac in emerging markets?.


? Why Choose Tonboli Liraglutide?

  • ? Research-grade GLP?1RA with reliable production

  • ?? NMPA-approved and China-manufactured, ensuring traceability

  • ? Prefilled pen offers precise dosing for studies

  • ? Supports robust metabolic, peptide pharmacokinetics, and cardiovascular research pipelines


? Related Research Agents

  • Semaglutide Injection (Ozempic®) – GLP?1 RA

  • Dual GLP?1/GIP Agonist Peptide Pharmaceuticals

  • Sitagliptin – DPP?4 Inhibitor Tablets

  • Empagliflozin – SGLT?2 Inhibitor Tablets


? Summary

Tonboli Liraglutide 18?mg/3?ml prefilled pen is a domestically approved GLP?1RA suitable for research into metabolic and cardiovascular pathways. With high regulatory confidence, peptide-level precision, and prefilled format, it’s well-suited for academic and lab settings.
?? Strictly for laboratory research or analytical use only — not for human consumption or therapy.

其他信息

重量 1.1 公斤
尺寸 26 × 25 × 28 厘米

Liraglutide Injection 18?mg/3?ml Prefilled Pen | Tonboli by Tonghua Dongbao | 有 1 个评价

  1. david

    thank you friend

添加评价

您的邮箱地址不会被公开。 必填项已用 * 标注

EMI Options

Select at least 2 products
to compare